In last trading session, Leap Therapeutics, Inc. (NASDAQ:LPTX) saw 1,435,682 shares changing hands with its beta currently measuring 1.97. Company’s recent per share price level of $2.23 trading at $0.1 or 4.69% at ring of the bell on the day assigns it a market valuation of $124.99 Million. That closing price of LPTX’s stock is at a discount of -42.6% from its 52-week high price of $3.18 and is indicating a premium of 74.3% from its 52-week low price of $0.573. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.38 Million shares which gives us an average trading volume of 441.74 Million if we extend that period to 3-months.

For Leap Therapeutics, Inc. (LPTX), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while 2 recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.16 in the current quarter.

Leap Therapeutics, Inc. (NASDAQ:LPTX) trade information

Upright in the green today for gaining 4.69%, in the last five days LPTX remained trading in the green while hitting it’s week-highest on Thursday, Jun 25 when the stock touched $2.32-3 price level, adding 3.88% to its value on the day. Leap Therapeutics, Inc.’s shares saw a change of 99.11% in year-to-date performance and have moved 9.31% in past 5-day. Leap Therapeutics, Inc. (NASDAQ:LPTX) showed a performance of 4.69% in past 30-days. Number of shares sold short was 1.43 Million shares which calculate 0 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $5.38 to the stock, which implies a rise of 141.26% to its current value. Analysts have been projecting $2.5 as a low price target for the stock while placing it at a high target of $8. It follows that stock’s current price would jump +258.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of 12.11% for stock’s current value.

Leap Therapeutics, Inc. (LPTX) estimates and forecasts

3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $830Million for the same. And 3 analysts are in estimates of company making revenue of $830Million in the next quarter that will end in September 01, 2020.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.4% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 10% while estimates for its earnings growth in next 5 years are of -2.49%

Leap Therapeutics, Inc. (NASDAQ:LPTX)’s Major holders

Insiders are in possession of 20.06% of company’s total shares while institution are holding 48.18% percent of that, with stock having share float percentage of 60.28%. Investors also watch the number of corporate investors in a company very closely, which is 24 institutions for Leap Therapeutics, Inc. that are currently holding shares of the company. Perceptive Advisors Llc is the top institutional holder at LPTX for having 6.73 Million shares of worth $10.63 Million. And as of March 30, 2020, it was holding 18.79% of the company’s outstanding shares.

The second largest institutional holder is Sio Capital Management, LLC, which was holding about 1.1 Million shares on March 30, 2020. The number of shares represents firm’s hold over 3.07% of outstanding shares, having a total worth of $1.74 Million.

On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Pharmaceuticals are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 477317 shares of worth $754.16 Thousand or 1.33% of the total outstanding shares. The later fund manager was in possession of 254.9 Thousand shares on February 28, 2020, making its stake of worth around $614.31 Thousand in the company or a holder of 0.71% of company’s stock.